LncRNA MNX1-AS1 promotes ovarian cancer process via targeting the miR-744-5p/SOX12 axis

Abstract

Purpose Ovarian cancer (OC) is the most common malignancy in women with high mortality. Increasing studies have revealed that long non-coding RNA (lncRNA) MNX1-AS1 has a promoting effect on various cancers. However, the mechanisms of MNX1-AS1 in OC are still unclear. Therefore, this study focused on exploring the mechanisms of MNX1-AS1 in OC. Materials and methods The expression of SOX12 at the protein level was detected by western blot. Cell proliferation was detected by CCK8 assay and colony formation assay. Cell cycle and cell apoptosis were detected by flow cytometry. Wound-healing assay, transwell assay and western blot were used to detect the ability of cell migration and invasion. The target binding was confirmed through the luciferase reporter assay. Results The expression of MNX1-AS1 was increased in OC tumor tissues and cells. Elevated MNX1-AS1 expression is associated with advanced stage and lower overall survival rate. Knockdown of MNX1-AS1 inhibited cell proliferation, migration and invasion, blocked cell cycle, and promoted cell apoptosis in SKOV-3 and OVCAR-3 cells. MNX1-AS1 was competitively binding with miR-744-5p, and its downstream target gene was SOX12. miR-544-5p expression was decreased, while SOX12 expression was increased in OC tumor tissues and cells. Overexpression of miR-744-5p inhibited cell proliferation, migration, invasion and promoted cell apoptosis in SKOV-3 and OVCAR-3 cells. Conclusion MNX1-AS1 promoted the development of OC through miR-744-5p/SOX12 axis. This study revealed a novel mechanism of MNX1-AS1 in OC, which may provide a new treatment or scanning target for OC.

Pan-Cancer Analysis Identifies MNX1 and Associated Antisense Transcripts as Biomarkers for Cancer

“…The significant differential expression between normal and tumour tissues suggested that these genes can serve as hallmark diagnostic markers for various cancers. These observations are in line with previous reports describing overexpression of MNX1 in cancers of the colon [ 15 ], breast [ 11 , 12 ], prostate [ 13 ], and glioma [ 17 ], as well as MNX1 - AS1 in breast [ 28 ], colon [ 29 ], oesophageal [ 30 ], stomach [ 31 ], glioblastoma [ 32 ], liver [ 33 ], lung [ 34 ], ovarian [ 35 , 36 ], and prostate [ 37 ] tumours. MNX1 was not found to be significantly overexpressed in liver cancer samples from TCGA compared to healthy liver tissue from GTEx, despite reports of upregulation in hepatocellular carcinoma [ 18 ].…”

Long non-coding RNA MYU promotes ovarian cancer cell proliferation by sponging miR-6827-5p and upregulating HMGA1

“…LncRNAs are expected to become molecular markers and therapeutic targets for tumor diagnosis and prognosis (18). The function of several lncRNAs has been revealed in ovarian cancer, such as MALAT1 (19), HOTAIR (20), CCAT1 (21)、NEAT1 ( 22), MNX1-AS1 (23).…”

MicroRNA expression profile of cholesterol metabolism analysis mediated by Thelenota ananas desulfated holothurin A saponin in RAW264.7 macrophage-foam cells

“…34 The overexpression of miR-744-5p inhibits cell proliferation, migration, and invasion. 35 In addition, the downregulation of miR-744-5p was also reported to be associated with signaling pathways related to glucose and lipid metabolism. 36 MiR-330 was also found to promote cell proliferation in human glioblastoma cells and vascular endothelial cells by regulating the SH3-domain GRB2-like 2 and WNT signaling pathways, respectively.…”